Deregulated sphingolipid metabolism and membrane organization in neurodegenerative disorders

Molecular Neurobiology

Volumn 41, Issue 2-3, 2010, Pages 314-340

  Piccinini, Marco ^b   Scandroglio, Federica ^a   Prioni, Simona ^a   Buccinnà, Barbara ^b   Loberto, Nicoletta ^a   Aureli, Massimo ^a   Chigorno, Vanna ^a   Lupino, Elisa ^b   DeMarco, Giovanni ^b   Lomartire, Annarosa ^b   Rinaudo, Maria Teresa ^b   Sonnino, Sandro ^a   Prinetti, Alessandro ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Alzheimer's disease; Gangliosides; Glycosphingolipids; Parkinson's disease; Prion diseases; Sphingolipid storage diseases; Sphingolipids; Sphingomyelin

Indexed keywords

1 DEOXYNOJIRIMYCIN DERIVATIVE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; GANGLIOSIDE GM1; GANGLIOSIDE GM2; GLYCOSPHINGOLIPID; MYELIN; N BUTYL DEOXYNOJIRIMYCIN; PRION PROTEIN; SPHINGOLIPID; UNCLASSIFIED DRUG;

ALBERS SCHOENBERG DISEASE; ALZHEIMER DISEASE; AUTOSOMAL RECESSIVE DISORDER; BRAIN DISEASE; CELL DIFFERENTIATION; CELL MEMBRANE; CELL MIGRATION; CELL SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DEGENERATIVE DISEASE; DEREGULATION; ENZYME REPLACEMENT; EUKARYOTIC CELL; GOLGI COMPLEX; HUMAN; HUNTINGTON CHOREA; LIPID METABOLISM; LYSOSOME STORAGE DISEASE; MEMBRANE STRUCTURE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PATHOLOGY; PRION DISEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; SYMPTOMATIC EPILEPSY; SYNAPTIC TRANSMISSION; TAY SACHS DISEASE; ANIMAL; CARBOHYDRATE ANALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; LIPIDOSIS; METABOLISM; MOLECULAR GENETICS; MYELIN SHEATH; PATHOPHYSIOLOGY;

ANIMALS; CARBOHYDRATE CONFORMATION; CARBOHYDRATE SEQUENCE; CELL MEMBRANE; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; MYELIN SHEATH; NEURODEGENERATIVE DISEASES; PRION DISEASES; SPHINGOLIPIDOSES; SPHINGOLIPIDS;

EID: 77955088249     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12035-009-8096-6     Document Type: Conference Paper

References (330)

1. IUPAC-IUBMB Joint Commission on Biochemical Nomenclature (1998) Nomenclature of glycolipids. Carbohydr Res 312:167-175
2. Roisen FJ, Bartfeld H, Nagele R, Yorke G (1981) Ganglioside stimulation of axonal sprouting in vitro. Science 214:577-578
3. Schauer R (1982) Chemistry, metabolism, and biological functions of sialic acids. Adv Carbohydr Chem Biochem 40:131-234
4. Glebov OO, Nichols BJ (2004) Lipid raft proteins have a random distribution during localized activation of the T-cell receptor. Nat Cell Biol 6:238-243
5. Karlsson KA (1970) On the chemistry and occurrence of sphingolipid long-chain bases. Chem Phys Lipids 5:6-43
6. Lin J, Shaw AS (2005) Getting downstream without a raft. Cell 121:815-816
7. Sonnino S, Mauri L, Chigorno V, Prinetti A (2006) Gangliosides as components of lipid membrane domains. Glycobiology 17 (1):1R-13R
8. Sonnino S, Prinetti A, Mauri L, Chigorno V, Tettamanti G (2006) Dynamic and structural properties of sphingolipids as driving forces for the formation of membrane domains. Chem Rev 106:2111-2125
9. Levery SB (1991) 1H-NMR study of GM2 ganglioside: evidence that an interresidue amide-carboxyl hydrogen bond contributes to stabilization of a preferred conformation. Glycoconj J 8:484-492
10. Acquotti D, Cantu L, Ragg E, Sonnino S (1994) Geometrical and conformational properties of ganglioside GalNAc-GD1a, IV4GalNAcIV3Neu5AcII3Neu5AcGgOse4Cer. Eur J Biochem 225:271-288
11. Acquotti D, Fronza G, Ragg E, Sonnino S (1991) Three dimensional structure of GD1b and GD1b-monolactone ganglio-sides in dimethylsulphoxide: a nuclear Overhauser effect investigation supported by molecular dynamics calculations. Chem Phys Lipids 59:107-125
12. Acquotti D, Poppe L, Dabrowski J, von der Lieth GW, Sonnino S, Tettamanti G (1990) Three-dimensional structure of the oligosaccaride chain of GM1 ganglioside revealed by a distance-mapping procedure: a rotating and laboratory frame nuclear overhauser enhancement investigation of native glycolipid in dimethyl sulfoxide and in water-dodecylphosphocholine solutions. J Am Chem Soc 112:7772-7778
13. Brocca P, Acquotti D, Sonnino S (1996) Nuclear Overhauser effect investigation on GM1 ganglioside containing N-glycolyl-neuraminic acid (II3Neu5GcGgOse4Cer). Glycoconj J 13:57-62
14. Brocca P, Berthault P, Sonnino S (1998) Conformation of the oligosaccharide chain of G(M1) ganglioside in a carbohydrate-enriched surface. Biophys J 74:309-318
15. Brocca P, Cantu L, Sonnino S (1995) Aggregation properties of semisynthetic GD1a ganglioside (IV3Neu5AcII3Neu5AcG-gOse4Cer) containing an acetyl group as acyl moiety. Chem Phys Lipids 77:41-49
16. Cantù L, Corti M, Casellato R, Acquotti D, Sonnino S (1991) Aggregation properties of GD1b, II3Neu5Ac2GgOse4Cer, and of GD1b-lactone, II3[alpha-Neu5Ac-(2-8, 1-9)-alpha-Neu5Ac] GgOse4Cer, in aqueous solution. Chem Phys Lipids 60:111-118
17. Cantu L, Corti M, Sonnino S, Tettamanti G (1990) Evidence for spontaneous segregation phenomena in mixed micelles of gangliosides. Chem Phys Lipids 55:223-229
18. Masserini M, Freire E (1986) Thermotropic characterization of phosphatidylcholine vesicles containing ganglioside GM1 with homogeneous ceramide chain length. Biochemistry 25:1043-1049
19. Masserini M, Palestini P, Freire E (1989) Influence of glycolipid oligosaccharide and long-chain base composition on the thermo-tropic properties of dipalmitoylphosphatidylcholine large unilamellar vesicles containing gangliosides. Biochemistry 28:5029-5034
20. Masserini M, Palestini P, Venerando B, Fiorilli A, Acquotti D, Tettamanti G (1988) Interactions of proteins with ganglioside-enriched microdomains on the membrane: the lateral phase separation of molecular species of GD1a ganglioside, having homogeneous long-chain base composition, is recognized by Vibrio cholerae sialidase. Biochemistry 27:7973-7978
21. Poppe L, van Halbeek H, Acquotti D, Sonnino S (1994) Carbohydrate dynamics at a micellar surface: GD1a headgroup transformations revealed by NMR spectroscopy. Biophys J 66:1642-1652
22. Scarsdale JN, Prestegard JH, Yu RK (1990) NMR and computational studies of interactions between remote residues in gangliosides. Biochemistry 29:9843-9855
23. Siebert HC, Reuter G, Schauer R, von der Lieth CW, Dabrowski J (1992) Solution conformations of GM3 gangliosides containing different sialic acid residues as revealed by NOE-based distance mapping, molecular mechanics, and molecular dynamics calculations. Biochemistry 31:6962-6971
24. Sonnino S, Cantu L, Acquotti D, Corti M, Tettamanti G (1990) Aggregation properties of GM3 ganglioside (II3Neu5AcLacCer) in aqueous solutions. Chem Phys Lipids 52:231-241
25. Sonnino S, Cantu L, Corti M, Acquotti D, Kirschner G, Tettamanti G (1990) Aggregation properties of semisynthetic GM1 ganglioside (II3Neu5AcGgOse4Cer) containing an acetyl group as acyl moiety. Chem Phys Lipids 56:49-57
26. Sonnino S, Cantu L, Corti M, Acquotti D, Venerando B (1994) Aggregative properties of gangliosides in solution. Chem Phys Lipids 71:21-45
27. Ha JH, Spolar RS, Record MT Jr (1989) Role of the hydrophobic effect in stability of site-specific protein-DNA complexes. J Mol Biol 209:801-816
28. Bach D, Sela B, Miller IR (1982) Compositional aspects of lipid hydration. Chem Phys Lipids 31:381-394
29. Palestini P, Allietta M, Sonnino S, Tettamanti G, Thompson TE, Tillack TW (1995) Gel phase preference of ganglioside GM1 at low concentration in two-component, two-phase phosphatidylcholine bilayers depends upon the ceramide moiety. Biochim Biophys Acta 1235:221-230
30. Chan KF (1988) Ganglioside-modulated protein phosphorylation. Partial purification and characterization of a ganglioside-inhibited protein kinase in brain. J Biol Chem 263:568-574
31. Chan KF (1989) Ganglioside-modulated protein phosphorylation in muscle. Activation of phosphorylase b kinase by gangliosides. J Biol Chem 264:18632-18637
32. Bassi R, Chigorno V, Fiorilli A, Sonnino S, Tettamanti G (1991) Exogenous gangliosides GD1b and GD1b-lactone, stably associated to rat brain P2 subcellular fraction, modulate differently the process of protein phosphorylation. J Neurochem 57:1207-1211
33. Bremer EG, Hakomori S, Bowen-Pope DF, Raines E, Ross R (1984) Ganglioside-mediated modulation of cell growth, growth factor binding, and receptor phosphorylation. J Biol Chem 259:6818-6825
34. Goldenring JR, Otis LC, Yu RK, DeLorenzo RJ (1985) Calcium/ganglioside- dependent protein kinase activity in rat brain membrane. J Neurochem 44:1229-1234
35. Hakomori S, Igarashi Y (1995) Functional role of glycosphin-golipids in cell recognition and signaling. J Biochem (Tokyo) 118:1091-1103
36. Kim JY, Goldenring JR, DeLorenzo RJ, Yu RK (1986) Gangliosides inhibit phospholipid-sensitive Ca2+-dependent kinase phosphorylation of rat myelin basic proteins. J Neurosci Res 15:159-166
37. Nakajima J, Tsuji S, Nagai Y (1986) Bioactive gangliosides: analysis of functional structures of the tetrasialoganglioside GQ1b which promotes neurite outgrowth. Biochim Biophys Acta 876:65-71
38. Tsuji S, Arita M, Nagai Y (1983) GQ1b, a bioactive ganglioside that exhibits novel nerve growth factor (NGF)-like activities in the two neuroblastoma cell lines. J Biochem (Tokyo) 94:303-306
39. Tsuji S, Nakajima J, Sasaki T, Nagai Y (1985) Bioactive gangliosides. IV. Ganglioside GQ1b/Ca2+ dependent protein kinase activity exists in the plasma membrane fraction of neuroblastoma cell line, GOTO. J Biochem 97:969-972
40. Yates AJ, Rampersaud A (1998) Sphingolipids as receptor modulators. An overview. Ann N Y Acad Sci 845:57-71
41. Valaperta R, Chigorno V, Basso L, Prinetti A, Bresciani R, Preti A, Miyagi T, Sonnino S (2006) Plasma membrane production of ceramide from ganglioside GM3 in human fibroblasts. Faseb J 20:1227-1229
42. Tettamanti G (2004) Ganglioside/glycosphingolipid turnover: new concepts. Glycoconj J 20:301-317
43. Kolter T, Proia RL, Sandhoff K (2002) Combinatorial ganglioside biosynthesis. J Biol Chem 277:25859-25862
44. van Echten G, Sandhoff K (1993) Ganglioside metabolism. Enzymology, topology, and regulation. J Biol Chem 268:5341-5344
45. Pewzner-Jung Y, Ben-Dor S, Futerman AH (2006) When do Lasses (longevity assurance genes) become CerS (ceramide synthases)?: insights into the regulation of ceramide synthesis. J Biol Chem 281:25001-25005
46. Yamaoka S, Miyaji M, Kitano T, Umehara H, Okazaki T (2004) Expression cloning of a human cDNA restoring sphingomyelin synthesis and cell growth in sphingomyelin synthase-defective lymphoid cells. J Biol Chem 279:18688-18693
47. Hanada K, Kumagai K, Tomishige N, Yamaji T (2009) CERT-mediated trafficking of ceramide. Biochim Biophys Acta 1791:684-691
48. Sprong H, Kruithof B, Leijendekker R, Slot JW, van Meer G, van der Sluijs P (1998) UDP-galactose:ceramide galactosyltransferase is a class I integral membrane protein of the endoplasmic reticulum, J Biol Chem, 273, 25880-25888
49. Yamaji T, Kumagai K, Tomishige N, Hanada K (2008) Two sphingolipid transfer proteins, CERT and FAPP2: their roles in sphingolipid metabolism. IUBMB Life 60:511-518
50. Warnock DE, Lutz MS, Blackburn WA, Young WW Jr, Baenziger JU (1994) Transport of newly synthesized glucosyl-ceramide to the plasma membrane by a non-Golgi pathway. Proc Natl Acad Sci USA 91:2708-2712
51. Riboni L, Bassi R, Prinetti A, Tettamanti G (1996) Salvage of catabolic products in ganglioside metabolism: a study on rat cerebellar granule cells in culture. FEBS Lett 391:336-340
52. Riboni L, Bassi R, Tettamanti G (1994) Effect of brefeldin A on ganglioside metabolism in cultured neurons: implications for the intracellular traffic of gangliosides. J Biochem (Tokyo) 116:140-146
53. Hannun YA (1994) The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem 269:3125-3128
54. Goni FM, Alonso A (2002) Sphingomyelinases: enzymology and membrane activity. FEBS Lett 531:38-46
55. Levade T, Jaffrezou JP (1999) Signalling sphingomyelinases: which, where, how and why? Biochim Biophys Acta 1438:1-17
56. Huitema K, van den Dikkenberg J, Brouwers JF, Holthuis JC (2004) Identification of a family of animal sphingomyelin synthases. Embo J 23:33-44
57. Slife CW, Wang E, Hunter R, Wang S, Burgess C, Liotta DC, Merrill AH Jr (1989) Free sphingosine formation from endogenous substrates by a liver plasma membrane system with a divalent cation dependence and a neutral pH optimum. J Biol Chem 264:10371-10377
58. Tani M, Iida H, Ito M (2003) O-glycosylation of mucin-like domain retains the neutral ceramidase on the plasma membranes as a type II integral membrane protein. J Biol Chem 278:10523-10530
59. Tani M, Sano T, Ito M, Igarashi Y (2005) Mechanisms of sphingosine and sphingosine 1-phosphate generation in human platelets. J Lipid Res 46:2458-2467
60. Schengrund CL, Rosenberg A (1970) Intracellular location and properties of bovine brain sialidase. J Biol Chem 245:6196-6200
61. Tettamanti G, Morgan IG, Gombos G, Vincendon G, Mandel P (1972) Sub-synaptosomal localization of brain particulate neuraminidose. Brain Res 47:515-518
62. Tettamanti G, Preti A, Lombardo A, Bonali F, Zambotti V (1973) Parallelism of subcellular location of major particulate neuraminidase and gangliosides in rabbit brain cortex. Biochim Biophys Acta 306:466-477
63. Tettamanti G, Preti A, Lombardo A, Suman T, Zambotti V (1975) Membrane-bound neuraminidase in the brain of different animals: behaviour of the enzyme on endogenous sialo derivatives and rationale for its assay. J Neurochem 25:451-456
64. Preti A, Fiorilli A, Lombardo A, Caimi L, Tettamanti G (1980) Occurrence of sialyltransferase activity in the synaptosomal membranes prepared from calf brain cortex. J Neurochem 35:281-296
65. Matsui Y, Lombard D, Massarelli R, Mandel P, Dreyfus H (1986) Surface glycosyltransferase activities during development of neuronal cell cultures. J Neurochem 46:144-150
66. Durrie R, Rosenberg A (1989) Anabolic sialosylation of gangliosides in situ in rat brain cortical slices. J Lipid Res 30:1259-1266
67. Durrie R, Saito M, Rosenberg A (1988) Endogenous glycosphingolipid acceptor specificity of sialosyltransferase systems in intact Golgi membranes, synaptosomes, and synaptic plasma membranes from rat brain. Biochemistry 27:3759-3764
68. Iwamori M, Iwamori Y (2005) Changes in the glycolipid composition and characteristic activation of GM3 synthase in the thymus of mouse after administration of dexamethasone. Glycoconj J 22:119-126
69. Kopitz J, Muhl C, Ehemann V, Lehmann C, Cantz M (1997) Effects of cell surface ganglioside sialidase inhibition on growth control and differentiation of human neuroblastoma cells. Eur J Cell Biol 73:1-9
70. Kopitz J, Sinz K, Brossmer R, Cantz M (1997) Partial characterization and enrichment of a membrane-bound sialidase specific for gangliosides from human brain tissue. Eur J Biochem 248:527-534
71. Riboni L, Prinetti A, Bassi R, Tettamanti G (1991) Cerebellar granule cells in culture exhibit a ganglioside-sialidase presumably linked to the plasma membrane. FEBS Lett 287:42-46
72. Kopitz J, von Reitzenstein C, Sinz K, Cantz M (1996) Selective ganglioside desialylation in the plasma membrane of human neuroblastoma cells. Glycobiology 6:367-376
73. Hata K, Wada T, Hasegawa A, Kiso M, Miyagi T (1998) Purification and characterization of a membrane-associated ganglioside sialidase from bovine brain. J Biochem (Tokyo) 123:899-905
74. Wada T, Yoshikawa Y, Tokuyama S, Kuwabara M, Akita H, Miyagi T (1999) Cloning, expression, and chromosomal mapping of a human ganglioside sialidase. Biochem Biophys Res Commun 261:21-27
75. Miyagi T, Wada T, Iwamatsu A, Hata K, Yoshikawa Y, Tokuyama S, Sawada M (1999) Molecular cloning and characterization of a plasma membrane-associated sialidase specific for gangliosides. J Biol Chem 274:5004-5011
76. Hasegawa T, Yamaguchi K, Wada T, Takeda A, Itoyama Y, Miyagi T (2000) Molecular cloning of mouse ganglioside sialidase and its increased expression in neuro2a cell differentiation. J Biol Chem 275:14778
77. Papini N, Anastasia L, Tringali C, Croci G, Bresciani R, Yamaguchi K, Miyagi T, Preti A, Prinetti A, Prioni S, Sonnino S, Tettamanti G, Venerando B, Monti E (2004) The plasma membrane-associated sialidase MmNEU3 modifies the ganglioside pattern of adjacent cells supporting its involvement in cell-to-cell interactions. J Biol Chem 279:16989-16995
78. Aureli M, Masilamani AP, Illuzzi G, Loberto N, Scandroglio F, Prinetti A, Chigorno V, Sonnino S (2009) Activity of plasma membrane beta-galactosidase and beta-glucosidase. FEBS Lett 583:2469-2473
79. Mencarelli S, Cavalieri C, Magini A, Tancini B, Basso L, Lemansky P, Hasilik A, Li YT, Chigorno V, Orlacchio A, Emiliani C, Sonnino S (2005) Identification of plasma membrane associated mature beta-hexosaminidase A, active towards GM2 ganglioside, in human fibroblasts. FEBS Lett 579:5501-5506
80. Reddy A, Caler EV, Andrews NW (2001) Plasma membrane repair is mediated by Ca(2+)-regulated exocytosis of lysosomes. Cell 106:157-169
81. Chigorno V, Giannotta C, Ottico E, Sciannamblo M, Mikulak J, Prinetti A, Sonnino S (2005) Sphingolipid uptake by cultured cells: complex aggregates of cell sphingolipids with serum proteins and lipoproteins are rapidly catabolized. J Biol Chem 280:2668-2675
82. Deng W, Li R, Ladisch S (2000) Influence of cellular ganglioside depletion on tumor formation. J Natl Cancer Inst 92:912-917
83. Dolo V, Li R, Dillinger M, Flati S, Manela J, Taylor BJ, Pavan A, Ladisch S (2000) Enrichment and localization of ganglioside G(D3) and caveolin-1 in shed tumor cell membrane vesicles. Biochim Biophys Acta 1486:265-274
84. Kong Y, Li R, Ladisch S (1998) Natural forms of shed tumor gangliosides. Biochim Biophys Acta 1394:43-56
85. McKallip R, Li R, Ladisch S (1999) Tumor gangliosides inhibit the tumor-specific immune response. J Immunol 163:3718-3726
86. Ichikawa S, Nakajo N, Sakiyama H, Hirabayashi Y (1994) A mouse B16 melanoma mutant deficient in glycolipids. Proc Natl Acad Sci USA 91:2703-2707
87. Kolter T, Magin TM, Sandhoff K (2000) Biomolecule function: no reliable prediction from cell culture. Traffic 1:803-804
88. Yamashita T, Wada R, Sasaki T, Deng C, Bierfreund U, Sandhoff K, Proia RL (1999) A vital role for glycosphingolipid synthesis during development and differentiation. Proc Natl Acad Sci USA 96:9142-9147
89. Dreyfus H, Louis JC, Harth S, Mandel P (1980) Gangliosides in cultured neurons. Neuroscience 5:1647-1655
90. Ngamukote S, Yanagisawa M, Ariga T, Ando S, Yu RK (2007) Developmental changes of glycosphingolipids and expression of glycogenes in mouse brains. J Neurochem 103:2327-2341
91. Svennerholm L,BostromK,FredmanP, Mansson JE, Rosengren B, Rynmark BM (1989) Human brain gangliosides: developmental changes from early fetal stage to advanced age. Biochim Biophys Acta 1005:109-117
92. Prinetti A, Chigorno V, Prioni S, Loberto N, Marano N, Tettamanti G, Sonnino S (2001) Changes in the lipid turnover, composition, and organization, as sphingolipid-enriched membrane domains, in rat cerebellar granule cells developing in vitro. J Biol Chem 276:21136-21145
93. Prinetti A, Prioni S, Chigorno V, Karagogeos D, Tettamanti G, Sonnino S (2001) Immunoseparation of sphingolipid-enriched membrane domains enriched in Src family protein tyrosine kinases and in the neuronal adhesion molecule TAG-1 by anti-GD3 ganglioside monoclonal antibody. J Neurochem 78:1162-1167
94. Prioni S, Loberto N, Prinetti A, Chigorno V, Guzzi F, Maggi R, Parenti M, Sonnino S (2002) Sphingolipid metabolism and caveolin expression in gonadotropin-releasing hormone-expressing GN11 and gonadotropin-releasing hormone-secreting GT1-7 neuronal cells. Neurochem Res 27:831-840
95. Riboni L, Prinetti A, Pitto M, Tettamanti G (1990) Patterns of endogenous gangliosides and metabolic processing of exogenous gangliosides in cerebellar granule cells during differentiation in culture. Neurochem Res 15:1175-1183
96. Rosenberg A, Sauer A, Noble EP, Gross HJ, Chang R, Brossmer R (1992) Developmental patterns of ganglioside sialosylation coincident with neuritogenesis in cultured embryonic chick brain neurons. J Biol Chem 267:10607-10612
97. Yavin Z, Yavin E (1978) Immunofluorescent patterns of dissociated rat embryo cerebral cells during development in surface culture: distinctive reactions with neurite and perikaryon cell membranes. Dev Neurosci 1:31-40
98. Ohsawa T (1989) Changes of mouse brain gangliosides during aging from young adult until senescence. Mech Ageing Dev 50:169-177
99. Barrier L, Ingrand S, Damjanac M, Rioux Bilan A, Hugon J, Page G (2007) Genotype-related changes of ganglioside composition in brain regions of transgenic mouse models of Alzheimer's disease. Neurobiol Aging 28:1863-1872
100. Svennerholm L, Bostrom K, Helander CG, Jungbjer B (1991) Membrane lipids in the aging human brain. J Neurochem 56:2051-2059
101. Svennerholm L, Bostrom K, Jungbjer B, Olsson L (1994) Membrane lipids of adult human brain: lipid composition of frontal and temporal lobe in subjects of age 20 to 100 years. J Neurochem 63:1802-1811
102. Svennerholm L, Gottfries CG (1994) Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J Neurochem 62:1039-1047
103. Pfeiffer SE, Warrington AE, Bansal R (1993) The oligodendrocyte and its many cellular processes. Trends Cell Biol 3:191-197
104. Byrne MC, Ledeen RW, Roisen FJ, Yorke G, Sclafani JR (1983) Ganglioside-induced neuritogenesis: verification that ganglio-sides are the active agents, and comparison of molecular species. J Neurochem 41:1214-1222
105. Facci L, Leon A, Toffano G, Sonnino S, Ghidoni R, Tettamanti G (1984) Promotion of neuritogenesis in mouse neuroblastoma cells by exogenous gangliosides. Relationship between the effect and the cell association of ganglioside GM1. J Neurochem 42:299-305
106. Kadowaki H, Evans JE, Rys-Sikora KE, Koff RS (1990) Effect of differentiation and cell density on glycosphingolipid class and molecular species composition of mouse neuroblastoma NB2a cells. J Neurochem 54:2125-2137
107. Tettamanti G, Riboni L (1994) Gangliosides turnover and neural cells function: a new perspective. Prog Brain Res 101:77-100
108. Tsuji S, Yamashita T, Tanaka M, Nagai Y (1988) Synthetic sialyl compounds as well as natural gangliosides induce neuritogenesis in a mouse neuroblastoma cell line (Neuro2a). J Neurochem 50:414-423
109. Ferrari G, Fabris M, Gorio A (1983) Gangliosides enhance neurite outgrowth in PC12 cells. Brain Res 284:215-221
110. Mutoh T, Hamano T, Yano S, Koga H, Yamamoto H, Furukawa K, Ledeen RW (2002) Stable transfection of GM1 synthase gene into GM1-deficient NG108-15 cells, CR-72 cells, rescues the responsiveness of Trk-neurotrophin receptor to its ligand, NGF. Neurochem Res 27:801-806
111. Mutoh T, Tokuda A, Miyadai T, Hamaguchi M, Fujiki N (1995) Ganglioside GM1 binds to the Trk protein and regulates receptor function. Proc Natl Acad Sci USA 92:5087-5091
112. Wu G, Lu ZH, Ledeen RW (1996) GM1 ganglioside modulates prostaglandin E1 stimulated adenylyl cyclase in neuro-2A cells. Glycoconj J 13:235-239
113. Wu GS, Lu ZH, Ledeen RW (1991) Correlation of gangliotetraose gangliosides with neurite forming potential of neuroblastoma cells. Brain Res Dev Brain Res 61:217-228
114. Prinetti A, Iwabuchi K, Hakomori S (1999) Glycosphingolipid-enriched signaling domain in mouse neuroblastoma Neuro2a cells. Mechanism of ganglioside-dependent neuritogenesis. J Biol Chem 274:20916-20924
115. Lam RS, Shaw AR, Duszyk M (2004) Membrane cholesterol content modulates activation of BK channels in colonic epithelia. Biochim Biophys Acta 1667:241-248
116. Naslavsky N, Shmeeda H, Friedlander G, Yanai A, Futerman AH, Barenholz Y, Taraboulos A (1999) Sphingolipid depletion increases formation of the scrapie prion protein in neuroblastoma cells infected with prions. J Biol Chem 274:20763-20771
117. Kasahara K, Watanabe K, Takeuchi K, Kaneko H, Oohira A, Yamamoto T, Sanai Y (2000) Involvement of gangliosides in glycosylphosphatidylinositol-anchored neuronal cell adhesion molecule TAG-1 signaling in lipid rafts. J Biol Chem 275:34701-34709
118. Inokuchi JI, Uemura S, Kabayama K, Igarashi Y (2000) Glycosphingolipid deficiency affects functional microdomain formation in Lewis lung carcinoma cells. Glycoconj J 17:239-245
119. Mitsuzuka K, Handa K, Satoh M, Arai Y, Hakomori S (2005) A specific microdomain ("glycosynapse 3") controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha3beta1 integrin with CD9. J Biol Chem 280:35545-35553
120. Nagafuku M, Kabayama K, Oka D, Kato A, Tani-ichi S, Shimada Y, Ohno-Iwashita Y, Yamasaki S, Saito T, Iwabuchi K, Hamaoka T, Inokuchi J, Kosugi A (2003) Reduction of glycosphingolipid levels in lipid rafts affects the expression state and function of glycosylphosphatidylinositol-anchored proteins but does not impair signal transduction via the T cell receptor. J Biol Chem 278:51920-51927
121. Sato T, Zakaria AM, Uemura S, Ishii A, Ohno-Iwashita Y, Igarashi Y, Inokuchi J (2005) Role for up-regulated ganglioside biosynthesis and association of Src family kinases with microdomains in retinoic acid-induced differentiation of F9 embryonal carcinoma cells. Glycobiology 15:687-699
122. Toledo MS, Suzuki E, Handa K, Hakomori S (2004) Cell growth regulation through GM3-enriched microdomain (glycosynapse) in human lung embryonal fibroblast WI38 and its oncogenic transformant VA13. J Biol Chem 279:34655-34664
123. Yanagisawa M, Nakamura K, Taga T (2005) Glycosphingolipid synthesis inhibitor represses cytokine-induced activation of the Ras-MAPK pathway in embryonic neural precursor cells. J Biochem (Tokyo) 138:285-291
124. Chang MC, Wisco D, Ewers H, Norden C, Winckler B (2006) Inhibition of sphingolipid synthesis affects kinetics but not fidelity of L1/NgCAM transport along direct but not transcytotic axonal pathways. Mol Cell Neurosci 31:525-538
125. Decker L, Baron W, Ffrench-Constant C (2004) Lipid rafts: microenvironments for integrin-growth factor interactions in neural development. Biochem Soc Trans 32:426-430
126. Kilkus J, Goswami R, Testai FD, Dawson G (2003) Ceramide in rafts (detergent-insoluble fraction) mediates cell death in neurotumor cell lines. J Neurosci Res 72:65-75
127. Ledesma MD, Simons K, Dotti CG (1998) Neuronal polarity: essential role of protein-lipid complexes in axonal sorting. Proc Natl Acad Sci USA 95:3966-3971
128. Harel R, Futerman AH (1993) Inhibition of sphingolipid synthesis affects axonal outgrowth in cultured hippocampal neurons. J Biol Chem 268:14476-14481
129. Schwarz A, Rapaport E, Hirschberg K, Futerman AH (1995) A regulatory role for sphingolipids in neuronal growth. Inhibition of sphingolipid synthesis and degradation have opposite effects on axonal branching. J Biol Chem 270:10990-10998
130. Usuki S, Hamanoue M, Kohsaka S, Inokuchi J (1996) Induction of ganglioside biosynthesis and neurite outgrowth of primary cultured neurons by L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol. J Neurochem 67:1821-1830
131. Inokuchi J, Mizutani A, Jimbo M, Usuki S, Yamagishi K, Mochizuki H, Muramoto K, Kobayashi K, Kuroda Y, Iwasaki K, Ohgami Y, Fujiwara M (1997) Up-regulation of ganglioside biosynthesis, functional synapse formation, and memory retention by a synthetic ceramide analog (L-PDMP). Biochem Biophys Res Commun 237:595-600
132. Rosner H (1998) Significance of gangliosides in neuronal differentiation of neuroblastoma cells and neurite growth in tissue culture. Ann N Y Acad Sci 845:200-214
133. Mutoh T, Rudkin BB, Koizumi S, Guroff G (1988) Nerve growth factor, a differentiating agent, and epidermal growth factor, a mitogen, increase the activities of different S6 kinases in PC12 cells. J Biol Chem 263:15853-15856
134. Jennemann R, Sandhoff R, Wang S, Kiss E, Gretz N, Zuliani C, Martin-Villalba A, Jager R, Schorle H, Kenzelmann M, Bonrouhi M, Wiegandt H, Grone HJ (2005) Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birth. Proc Natl Acad Sci USA 102:12459-12464
135. Kojima N, Kurosawa N, Nishi T, Hanai N, Tsuji S (1994) Induction of cholinergic differentiation with neurite sprouting by de novo biosynthesis and expression of GD3 and b-series gangliosides in Neuro2a cells. J Biol Chem 269:30451-30456
136. Kanda T, Ariga T, Yamawaki M, Pal S, Katoh-Semba R, Yu RK (1995) Effect of nerve growth factor and forskolin on glycosyltransferase activities and expression of a globo-series glycosphingolipid in PC12D pheochromocytoma cells. J Neurochem 64:810-817
137. Boldin SA, Futerman AH (2000) Up-regulation of glucosylcer-amide synthesis upon stimulation of axonal growth by basic fibroblast growth factor. Evidence for post-translational modification of glucosylceramide synthase. J Biol Chem 275:9905-9909
138. Yu RK, Macala LJ, Taki T, Weinfield HM, Yu FS (1988) Developmental changes in ganglioside composition and synthesis in embryonic rat brain. J Neurochem 50:1825-1829
139. Yu RK, Nakatani Y, Yanagisawa M (2009) The role of glycosphingolipid metabolism in the developing brain. J Lipid Res 50(Suppl):S440-445
140. Proshin S, Yamaguchi K, Wada T, Miyagi T (2002) Modulation of neuritogenesis by ganglioside-specific sialidase (Neu 3) in human neuroblastoma NB-1 cells. Neurochem Res 27:841-846
141. von Reitzenstein C, Kopitz J, Schuhmann V, Cantz M (2001) Differential functional relevance of a plasma membrane ganglioside sialidase in cholinergic and adrenergic neuroblastoma cell lines. Eur J Biochem 268:326-333
142. Da Silva JS, Hasegawa T, Miyagi T, Dotti CG, Abad-Rodriguez J (2005) Asymmetric membrane ganglioside sialidase activity specifies axonal fate. Nat Neurosci 8:606-615
143. Rodriguez JA, Piddini E, Hasegawa T, Miyagi T, Dotti CG (2001) Plasma membrane ganglioside sialidase regulates axonal growth and regeneration in hippocampal neurons in culture. J Neurosci 21:8387-8395
144. Kusumi A, Suzuki K (2005) Toward understanding the dynamics of membrane-raft-based molecular interactions. Biochim Biophys Acta 1746:234-251
145. Prinetti A, Chigorno V, Mauri L, Loberto N, Sonnino S (2007) Modulation of cell functions by glycosphingolipid metabolic remodeling in the plasma membrane. J Neurochem 103(Suppl 1):113-125
146. Rajendran L, Simons K (2005) Lipid rafts and membrane dynamics. J Cell Sci 118:1099-1102
147. Tsui-Pierchala BA, Encinas M, Milbrandt J, Johnson EM Jr (2002) Lipid rafts in neuronal signaling and function. Trends Neurosci 25:412-417
148. Saarma M (2001) GDNF recruits the signaling crew into lipid rafts. Trends Neurosci 24:427-429
149. Chini B, Parenti M (2004) G-protein coupled receptors in lipid rafts and caveolae: how, when and why do they go theré J Mol Endocrinol 32:325-338
150. Kasahara K, Watanabe Y, YamamotoT,Sanai Y (1997) Association of Src family tyrosine kinase Lyn with ganglioside GD3 in rat brain. Possible regulation of Lyn by glycosphingolipid in caveolae-like domains. J Biol Chem 272:29947-29953
151. Nagappan G, Lu B (2005) Activity-dependent modulation of the BDNF receptor TrkB: mechanisms and implications. Trends Neurosci 28:464-471
152. Paratcha G, Ibanez CF (2002) Lipid rafts and the control of neurotrophic factor signaling in the nervous system: variations on a theme. Curr Opin Neurobiol 12:542-549
153. Prinetti A, Chigorno V, Tettamanti G, Sonnino S (2000) Sphingolipid-enriched membrane domains from rat cerebellar granule cells differentiated in culture. A compositional study. J Biol Chem 275:11658-11665
154. Prinetti A, Marano N, Prioni S, Chigorno V, Mauri L, Casellato R, Tettamanti G, Sonnino S (2000) Association of Src-family protein tyrosine kinases with sphingolipids in rat cerebellar granule cells differentiated in culture. Glycoconj J 17:223-232
155. Wu C, Butz S, Ying Y, Anderson RG (1997) Tyrosine kinase receptors concentrated in caveolae-like domains from neuronal plasma membrane. J Biol Chem 272:3554-3559
156. Decker L, Ffrench-Constant C (2004) Lipid rafts and integrin activation regulate oligodendrocyte survival. J Neurosci 24:3816-3825
157. Santuccione A, Sytnyk V, Leshchyns'ka I, Schachner M (2005) Prion protein recruits its neuronal receptor NCAM to lipid rafts to activate p59fyn and to enhance neurite outgrowth. J Cell Biol 169:341-354
158. Tooze SA, Martens GJ, Huttner WB (2001) Secretory granule biogenesis: rafting to the SNARE. Trends Cell Biol 11:116-122
159. McKerracher L (2002) Ganglioside rafts as MAG receptors that mediate blockade of axon growth. Proc Natl Acad Sci USA 99:7811-7813
160. Vyas AA, Patel HV, Fromholt SE, Heffer-Lauc M, Vyas KA, Dang J, Schachner M, Schnaar RL (2002) Gangliosides are functional nerve cell ligands for myelin-associated glycoprotein (MAG), an inhibitor of nerve regeneration. Proc Natl Acad Sci USA 99:8412-8417
161. Boggs JM, Wang H, Gao W, Arvanitis DN, Gong Y, Min W (2004) A glycosynapse in myelin? Glycoconj J 21:97-110
162. Eckhardt M (2008) The role and metabolism of sulfatide in the nervous system. Mol Neurobiol 37:93-103
163. Marcus J, Popko B (2002) Galactolipids are molecular determinants of myelin development and axo-glial organization. Biochim Biophys Acta 1573:406-413
164. Bosio A, Binczek E, Stoffel W (1996) Functional breakdown of the lipid bilayer of the myelin membrane in central and peripheral nervous system by disrupted galactocerebroside synthesis. Proc Natl Acad Sci USA 93:13280-13285
165. Coetzee T, Fujita N, Dupree J, Shi R, Blight A, Suzuki K, Popko B (1996) Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability. Cell 86:209-219
166. Hirahara Y, Bansal R, Honke K, Ikenaka K, Wada Y (2004) Sulfatide is a negative regulator of oligodendrocyte differentiation: development in sulfatide-null mice. Glia 45:269-277
167. Boggs JM, Gao W, Hirahara Y (2008) Myelin glycosphingolipids, galactosylceramide and sulfatide, participate in carbohydrate-carbohydrate interactions between apposed membranes and may form glycosynapses between oligodendrocyte and/or myelin membranes. Biochim Biophys Acta 1780:445-455
168. Taylor CM, Coetzee T, Pfeiffer SE (2002) Detergent-insoluble glycosphingolipid/cholesterol microdomains of the myelin membrane. J Neurochem 81:993-1004
169. Pan B, Fromholt SE, Hess EJ, Crawford TO, Griffin JW, Sheikh KA, Schnaar RL (2005) Myelin-associated glycoprotein and complementary axonal ligands, gangliosides, mediate axon stability in the CNS and PNS: neuropathology and behavioral deficits in single-and double-null mice. Exp Neurol 195:208-217
170. Schnaar RL, Lopez PH (2009) Myelin-associated glycoprotein and its axonal receptors. J Neurosci Res 87:3267-3276
171. Trapp BD (1990) Myelin-associated glycoprotein. Location and potential functions. Ann N Y Acad Sci 605:29-43
172. Schachner M, Bartsch U (2000) Multiple functions of the myelin-associated glycoprotein MAG (siglec-4a) in formation and maintenance of myelin. Glia 29:154-165
173. Quarles RH (2007) Myelin-associated glycoprotein (MAG): past, present and beyond. J Neurochem 100:1431-1448
174. Walsh FS, Doherty P (1997) Neural cell adhesion molecules of the immunoglobulin superfamily: role in axon growth and guidance. Annu Rev Cell Dev Biol 13:425-456
175. Erb M, Flueck B, Kern F, Erne B, Steck AJ, Schaeren-Wiemers N (2006) Unraveling the differential expression of the two isoforms of myelin-associated glycoprotein in a mouse expressing GFP-tagged S-MAG specifically regulated and targeted into the different myelin compartments. Mol Cell Neurosci 31:613-627
176. Miescher GC, Lutzelschwab R, Erne B, Ferracin F, Huber S, Steck AJ (1997) Reciprocal expression of myelin-associated glycoprotein splice variants in the adult human peripheral and central nervous systems. Brain Res Mol Brain Res 52:299-306
177. Burger D, Pidoux L, Steck AJ (1993) Identification of the glycosylated sequons of human myelin-associated glycoprotein. Biochem Biophys Res Commun 197:457-464
178. Voshol H, van Zuylen CW, Orberger G, Vliegenthart JF, Schachner M (1996) Structure of the HNK-1 carbohydrate epitope on bovine peripheral myelin glycoprotein P0. J Biol Chem 271:22957-22960
179. Crocker PR, Paulson JC, Varki A (2007) Siglecs and their roles in the immune system. Nat Rev Immunol 7:255-266
180. Kelm S, Pelz A, Schauer R, Filbin MT, Tang S, de Bellard ME, Schnaar RL, Mahoney JA, Hartnell A, Bradfield P et al (1994) Sialoadhesin, myelin-associated glycoprotein and CD22 define a new family of sialic acid-dependent adhesion molecules of the immunoglobulin superfamily. Curr Biol 4:965-972
181. Collins BE, Yang LJ, Mukhopadhyay G, Filbin MT, Kiso M, Hasegawa A, Schnaar RL (1997) Sialic acid specificity of myelin-associated glycoprotein binding. J Biol Chem 272:1248-1255
182. Vyas AA, Schnaar RL (2001) Brain gangliosides: functional ligands for myelin stability and the control of nerve regeneration. Biochimie 83:677-682
183. Yang LJ, Zeller CB, Shaper NL, Kiso M, Hasegawa A, Shapiro RE, Schnaar RL (1996) Gangliosides are neuronal ligands for myelin-associated glycoprotein. Proc Natl Acad Sci USA 93:814-818
184. Tang S, Shen YJ, DeBellard ME, Mukhopadhyay G, Salzer JL, Crocker PR, Filbin MT (1997) Myelin-associated glyco-protein interacts with neurons via a sialic acid binding site at ARG118 and a distinct neurite inhibition site. J Cell Biol 138:1355-1366
185. Jaramillo ML, Afar DE, Almazan G, Bell JC (1994) Identification of tyrosine 620 as the major phosphorylation site of myelin-associated glycoprotein and its implication in interacting with signaling molecules. J Biol Chem 269:27240-27245
186. Kursula P, Tikkanen G, Lehto VP, Nishikimi M, Heape AM (1999) Calcium-dependent interaction between the large myelin-associated glycoprotein and S100beta. J Neurochem 73:1724-1732
187. Umemori H, Kadowaki Y, Hirosawa K, Yoshida Y, Hironaka K, Okano H, Yamamoto T (1999) Stimulation of myelin basic protein gene transcription by Fyn tyrosine kinase for myelination. J Neurosci 19:1393-1397
188. Umemori H, Sato S, Yagi T, Aizawa S, Yamamoto T (1994) Initial events of myelination involve Fyn tyrosine kinase signalling. Nature 367:572-576
189. Fujita N, Kemper A, Dupree J, Nakayasu H, Bartsch U, Schachner M, Maeda N, Suzuki K, Popko B (1998) The cytoplasmic domain of the large myelin-associated glycoprotein isoform is needed for proper CNS but not peripheral nervous system myelination. J Neurosci 18:1970-1978
190. Kursula P, Lehto VP, Heape AM (2001) The small myelin-associated glycoprotein binds to tubulin and microtubules. Brain Res Mol Brain Res 87:22-30
191. Simons M, Kramer EM, Thiele C, Stoffel W, Trotter J (2000) Assembly of myelin by association of proteolipid protein with cholesterol-and galactosylceramide-rich membrane domains. J Cell Biol 151:143-154
192. Marta CB, Taylor CM, Cheng S, Quarles RH, Bansal R, Pfeiffer SE (2004) Myelin associated glycoprotein cross-linking triggers its partitioning into lipid rafts, specific signaling events and cytoskeletal rearrangements in oligodendrocytes. Neuron Glia Biol 1:35-46
193. Keita M, Magy L, Heape A, Richard L, Piaser M, Vallat JM (2002) Immunocytological studies of L-MAG expression regulation during myelination of embryonic brain cell cocultures. Dev Neurosci 24:495-503
194. Bartsch U (2003) Neural CAMS and their role in the development and organization of myelin sheaths. Front Biosci 8:d477-d490
195. Montag D, Giese KP, Bartsch U, Martini R, Lang Y, Bluthmann H, Karthigasan J, Kirschner DA, Wintergerst ES, Nave KA et al (1994) Mice deficient for the myelin-associated glycoprotein show subtle abnormalities in myelin. Neuron 13:229-246
196. Li C, Tropak MB, Gerlai R, Clapoff S, Abramow-Newerly W, Trapp B, Peterson A, Roder J (1994) Myelination in the absence of myelin-associated glycoprotein. Nature 369:747-750
197. Lassmann H, Bartsch U, Montag D, Schachner M (1997) Dying-back oligodendrogliopathy: a late sequel of myelin-associated glycoprotein deficiency. Glia 19:104-110
198. Fruttiger M, Montag D, Schachner M, Martini R (1995) Crucial role for the myelin-associated glycoprotein in the maintenance of axon-myelin integrity. Eur J NeuroSci 7:511-515
199. Loers G, Aboul-Enein F, Bartsch U, Lassmann H, Schachner M (2004) Comparison of myelin, axon, lipid, and immunopathology in the central nervous system of differentially myelin-compromised mutant mice: a morphological and biochemical study. Mol Cell Neurosci 27:175-189
200. Sandvig A, Berry M, Barrett LB, Butt A, Logan A (2004) Myelin-, reactive glia-, and scar-derived CNS axon growth inhibitors: expression, receptor signaling, and correlation with axon regeneration. Glia 46:225-251
201. McKerracher L, David S, Jackson DL, Kottis V, Dunn RJ, Braun PE (1994) Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth. Neuron 13:805-811
202. Mukhopadhyay G, Doherty P, Walsh FS, Crocker PR, Filbin MT (1994) A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. Neuron 13:757-767
203. Yiu G, He Z (2006) Glial inhibition of CNS axon regeneration. Nat Rev Neurosci 7:617-627
204. Vinson M, Strijbos PJ, Rowles A, Facci L, Moore SE, Simmons DL, Walsh FS (2001) Myelin-associated glycoprotein interacts with ganglioside GT1b. A mechanism for neurite outgrowth inhibition. J Biol Chem 276:20280-20285
205. Cao Z, Gao Y, Deng K, Williams G, Doherty P,Walsh FS (2009) Receptors for myelin inhibitors: Structures and therapeutic opportunities. Mol Cell Neurosci
206. Domeniconi M, Cao Z, Spencer T, Sivasankaran R, Wang K, Nikulina E, Kimura N, Cai H, Deng K, Gao Y, He Z, Filbin M (2002) Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. Neuron 35:283-290
207. Liu BP, Fournier A, GrandPre T, Strittmatter SM (2002) Myelin-associated glycoprotein as a functional ligand for the Nogo-66 receptor. Science 297:1190-1193
208. Venkatesh K, Chivatakarn O, Lee H, Joshi PS, Kantor DB, Newman BA, Mage R, Rader C, Giger RJ (2005) The Nogo-66 receptor homolog NgR2 is a sialic acid-dependent receptor selective for myelin-associated glycoprotein. J Neurosci 25:808-822
209. Williams G, Wood A, Williams EJ, Gao Y, Mercado ML, Katz A, Joseph-McCarthy D, Bates B, Ling HP, Aulabaugh A, Zaccardi J, Xie Y, Pangalos MN, Walsh FS, Doherty P (2008) Ganglioside inhibition of neurite outgrowth requires Nogo receptor function: identification of interaction sites and development of novel antagonists. J Biol Chem 283:16641-16652
210. Cao Z, Qiu J, Domeniconi M, Hou J, Bryson JB, Mellado W, Filbin MT (2007) The inhibition site on myelin-associated glycoprotein is within Ig-domain 5 and is distinct from the sialic acid binding site. J Neurosci 27:9146-9154
211. Mehta NR, Lopez PH, Vyas AA, Schnaar RL (2007) Gangliosides and Nogo receptors independently mediate myelin-associated glycoprotein inhibition of neurite outgrowth in different nerve cells. J Biol Chem 282:27875-27886
212. Venkatesh K, Chivatakarn O, Sheu SS, Giger RJ (2007) Molecular dissection of the myelin-associated glycoprotein receptor complex reveals cell type-specific mechanisms for neurite outgrowth inhibition. J Cell Biol 177:393-399
213. Hooper NM (2005) Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein. Biochem Soc Trans 33:335-338
214. Kazlauskaite J, Pinheiro TJ (2005) Aggregation and fibrillization of prions in lipid membranes. Biochem Soc Symp 211-222
215. Futerman AH, Sussman JL, Horowitz M, Silman I, Zimran A (2004) New directions in the treatment of Gaucher disease. Trends Pharmacol Sci 25:147-151
216. Futerman AH, van Meer G (2004) The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol 5:554-565
217. Kolter T, Sandhoff K (2006) Sphingolipid metabolism diseases. Biochim Biophys Acta 1758:2057-2079
218. Hein LK, Duplock S, Hopwood JJ, Fuller M (2008) Lipid composition of microdomains is altered in a cell model of Gaucher disease. J Lipid Res 49:1725-1734
219. Langeveld M, Ghauharali KJ, Sauerwein HP, Ackermans MT, Groener JE, Hollak CE, Aerts JM, Serlie MJ (2008) Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance. J Clin Endocrinol Metab 93:845-851
220. Kabayama K, Sato T, Saito K, Loberto N, Prinetti A, Sonnino S, Kinjo M, Igarashi Y, Inokuchi J (2007) Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance. Proc Natl Acad Sci USA 104:13678-13683
221. White AB, Givogri MI, Lopez-Rosas A, Cao H, van Breemen R, Thinakaran G, Bongarzone ER (2009) Psychosine accumulates in membrane microdomains in the brain of Krabbe patients, disrupting the raft architecture. J Neurosci 29:6068-6077
222. Schuchman EH (2007) The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. J Inherit Metab Dis 30:654-663
223. Buccinna B, Piccinini M, Prinetti A, Scandroglio F, Prioni S, Valsecchi M, Votta B, Grifoni S, Lupino E, Ramondetti C, Schuchman EH, Giordana MT, Sonnino S, Rinaudo MT (2009) Alterations of myelin-specific proteins and sphingolipids characterize the brains of acid sphingomyelinase-deficient mice, an animal model of Niemann-Pick disease type A. J Neurochem 109:105-115
224. Scandroglio F, Venkata JK, Loberto N, Prioni S, Schuchman EH, Chigorno V, Prinetti A, Sonnino S (2008) Lipid content of brain, brain membrane lipid domains, and neurons from acid sphingomyelinase deficient mice. J Neurochem 107:329-338
225. Ariga T, McDonald MP, Yu RK (2008) Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease\a review. J Lipid Res 49:1157-1175
226. Brooksbank BW, McGovern J (1989) Gangliosides in the brain in adult Down's syndrome and Alzheimer's disease. Mol Chem Neuropathol 11:143-156
227. Crino PB, Ullman MD, Vogt BA, Bird ED, Volicer L (1989) Brain gangliosides in dementia of the Alzheimer type. Arch Neurol 46:398-401
228. Kalanj S, Kracun I, Rosner H, Cosovic C (1991) Regional distribution of brain gangliosides in Alzheimer's disease. Neurol Croat 40:269-281
229. Kracun I, Kalanj S, Talan-Hranilovic J, Cosovic C (1992) Cortical distribution of gangliosides in Alzheimer's disease. Neurochem Int 20:433-438
230. Kracun I, Rosner H, Drnovsek V, Heffer-Lauc M, Cosovic C, Lauc G (1991) Human brain gangliosides in development, aging and disease. Int J Dev Biol 35:289-295
231. Cheng H, Xu J, McKeel DW Jr, Han X (2003) Specificity and potential mechanism of sulfatide deficiency in Alzheimer's disease: an electrospray ionization mass spectrometric study. Cell Mol Biol (Noisy-le-grand) 49:809-818
232. Cheng SH, Smith AE (2003) Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Gene Ther 10:1275-1281
233. Pitto M, Raimondo F, Zoia C, Brighina L, Ferrarese C, Masserini M (2005) Enhanced GM1 ganglioside catabolism in cultured fibroblasts from Alzheimer patients. Neurobiol Aging 26:833-838
234. Molander-Melin M, Blennow K, Bogdanovic N, Dellheden B, Mansson JE, Fredman P (2005) Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J Neurochem 92:171-182
235. Chapman J, Sela BA, Wertman E, Michaelson DM (1988) Antibodies to ganglioside GM1 in patients with Alzheimer's disease. Neurosci Lett 86:235-240
236. Katsel P, Li C, Haroutunian V (2007) Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's diseasé Neurochem Res 32:845-856
237. Ashall F, Goate AM (1994) Role of the beta-amyloid precursor protein in Alzheimer's disease. Trends Biochem Sci 19:42-46
238. Allinquant B, Hantraye P, Mailleux P, Moya K, Bouillot C, Prochiantz A (1995) Downregulation of amyloid precursor protein inhibits neurite outgrowth in vitro. J Cell Biol 128:919-927
239. Brouillet E, Trembleau A, Galanaud D, Volovitch M, Bouillot C, Valenza C, Prochiantz A, Allinquant B (1999) The amyloid precursor protein interacts with Go heterotrimeric protein within a cell compartment specialized in signal transduction. J Neurosci 19:1717-1727
240. Ikezu T, Trapp BD, Song KS, Schlegel A, Lisanti MP, Okamoto T (1998) Caveolae, plasma membrane microdo-mains for alpha-secretase-mediated processing of the amyloid precursor protein. J Biol Chem 273:10485-10495
241. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95:6460-6464
242. Giambarella U, Yamatsuji T, Okamoto T, Matsui T, Ikezu T, Murayama Y, Levine MA, Katz A, Gautam N, Nishimoto I (1997) G protein betagamma complex-mediated apoptosis by familial Alzheimer's disease mutant of APP. Embo J 16:4897-4907
243. Cordy JM, Hooper NM, Turner AJ (2006) The involvement of lipid rafts in Alzheimer's disease. Mol Membr Biol 23:111-122
244. Hartman T (2005) Cholesterol and Alzheimer's disease: statins, cholesterol depletion in APP processing and Abeta generation. Subcell Biochem 38:365-380
245. Zha Q, Ruan Y, Hartmann T, Beyreuther K, Zhang D (2004) GM1 ganglioside regulates the proteolysis of amyloid precursor protein. Mol Psychiatry 9:946-952
246. Tamboli IY, Prager K, Barth E, Heneka M, Sandhoff K, Walter J (2005) Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide. J Biol Chem 280:28110-28117
247. Sawamura N, Ko M, Yu W, Zou K, Hanada K, Suzuki T, Gong JS, Yanagisawa K, Michikawa M (2004) Modulation of amyloid precursor protein cleavage by cellular sphingolipids. J Biol Chem 279:11984-11991
248. Puglielli L, Ellis BC, Saunders AJ, Kovacs DM (2003) Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem 278:19777-19783
249. Ehehalt R, Keller P, Haass C, Thiele C, Simons K (2003) Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160:113-123
250. Kim SI, Yi JS, Ko YG (2006) Amyloid beta oligomerization is induced by brain lipid rafts. J Cell Biochem 99:878-889
251. Vetrivel KS, Cheng H, Kim SH, Chen Y, Barnes NY, Parent AT, Sisodia SS, Thinakaran G (2005) Spatial segregation of gamma-secretase and substrates in distinct membrane domains. J Biol Chem 280:25892-25900
252. Matsuzaki K (2007) Physicochemical interactions of amyloid beta-peptide with lipid bilayers. Biochim Biophys Acta 1768:1935-1942
253. Terzi E, Holzemann G, Seelig J (1995) Self-association of beta-amyloid peptide (1-40) in solution and binding to lipid membranes. J Mol Biol 252:633-642
254. Yanagisawa K, Odaka A, Suzuki N, Ihara Y (1995) GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Nat Med 1:1062-1066
255. Yanagisawa K, Ihara Y (1998) GM1 ganglioside-bound amyloid beta-protein in Alzheimer's disease brain. Neurobiol Aging 19: S65-S67
256. Kakio A, Nishimoto S, Yanagisawa K, Kozutsumi Y, Matsuzaki K (2002) Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 41:7385-7390
257. Utsumi M, Yamaguchi Y, Sasakawa H, Yamamoto N, Yanagisawa K, Kato K (2008) Up-and-down topological mode of amyloid beta-peptide lying on hydrophilic/hydrophobic interface of ganglioside clusters. Glycoconj J 26:999-1006
258. Wakabayashi M,Okada T, Kozutsumi Y, Matsuzaki K (2005) GM1 ganglioside-mediated accumulation of amyloid beta-protein on cell membranes. Biochem Biophys Res Commun 328:1019-1023
259. Yanagisawa K (2007) Role of gangliosides in Alzheimer's disease. Biochim Biophys Acta 1768:1943-1951
260. Hayashi H, Kimura N, Yamaguchi H, Hasegawa K, Yokoseki T, Shibata M, Yamamoto N, Michikawa M, Yoshikawa Y, Terao K, Matsuzaki K, Lemere CA, Selkoe DJ, Naiki H, Yanagisawa K (2004) A seed for Alzheimer amyloid in the brain. J Neurosci 24:4894-4902
261. Yamamoto N, Matsubara T, Sato T, Yanagisawa K (2008) Age-dependent high-density clustering of GM1 ganglioside at presynaptic neuritic terminals promotes amyloid beta-protein fibrillogenesis. Biochim Biophys Acta 1778:2717-2726
262. Ariga T, Kobayashi K, Hasegawa A, Kiso M, Ishida H, Miyatake T (2001) Characterization of high-affinity binding between gangliosides and amyloid beta-protein. Arch Biochem Biophys 388:225-230
263. Choo-Smith LP, Garzon-Rodriguez W, Glabe CG, Surewicz WK (1997) Acceleration of amyloid fibril formation by specific binding of Abeta-(1-40) peptide to ganglioside-containing membrane vesicles. J Biol Chem 272:22987-22990
264. Valdes-Gonzalez T, Inagawa J, Ido T (2001) Neuropeptides interact with glycolipid receptors: a surface plasmon resonance study. Peptides 22:1099-1106
265. Kakio A, Nishimoto SI, Yanagisawa K, Kozutsumi Y, Matsuzaki K (2001) Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J Biol Chem 276:24985-24990
266. Mizuno T, Nakata M, Naiki H, Michikawa M, Wang R, Haass C, Yanagisawa K (1999) Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture. J Biol Chem 274:15110-15114
267. Kakio A, Nishimoto S, Kozutsumi Y, Matsuzaki K (2003) Formation of a membrane-active form of amyloid beta-protein in raft-like model membranes. Biochem Biophys Res Commun 303:514-518
268. Yamamoto N, Hasegawa K, Matsuzaki K, Naiki H, Yanagisawa K (2004) Environment-and mutation-dependent aggregation behavior of Alzheimer amyloid beta-protein. J Neurochem 90:62-69
269. Yamamoto N, Hirabayashi Y, Amari M, Yamaguchi H, Romanov G, Van Nostrand WE, Yanagisawa K (2005) Assembly of hereditary amyloid beta-protein variants in the presence of favorable gangliosides. FEBS Lett 579:2185-2190
270. Yamamoto N, Matsuzaki K, Yanagisawa K (2005) Cross-seeding of wild-type and hereditary variant-type amyloid beta-proteins in the presence of gangliosides. J Neurochem 95:1167-1176
271. Yamamoto N, Yokoseki T, Shibata M, Yamaguchi H, Yanagisawa K (2005) Suppression of Abeta deposition in brain by peripheral administration of Fab fragments of anti-seed antibody. Biochem Biophys Res Commun 335:45-47
272. Oikawa N, Yamaguchi H, Ogino K, Taki T, Yuyama K, Yamamoto N, Shin RW, Furukawa K, Yanagisawa K (2009) Gangliosides determine the amyloid pathology of Alzheimer's disease. NeuroReport 20:1043-1046
273. Kimura N, Yanagisawa K (2007) Endosomal accumulation of GM1 ganglioside-bound amyloid beta-protein in neurons of aged monkey brains. NeuroReport 18:1669-1673
274. Yamamoto N, Matsubara E, Maeda S, Minagawa H, Takashima A, Maruyama W, Michikawa M, Yanagisawa K (2007) A ganglioside-induced toxic soluble Abeta assembly. Its enhanced formation from Abeta bearing the Arctic mutation. J Biol Chem 282:2646-2655
275. Dunbar GL, Sandstrom MI, Rossignol J, Lescaudron L (2006) Neurotrophic enhancers as therapy for behavioral deficits in rodent models of Huntington's disease: use of gangliosides, substituted pyrimidines, and mesenchymal stem cells. Behav Cogn Neurosci Rev 5:63-79
276. Goebel HH, Heipertz R, Scholz W, Iqbal K, Tellez-Nagel I (1978) Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies. Neurology 28:23-31
277. Heipertz R, Pilz H, Scholz W (1977) The fatty acid composition of sphingomyelin from adult human cerebral white matter and changes in childhood, senium and unspecific brain damage. J Neurol 216:57-65
278. Wherrett JR, Brown BL (1969) Erythrocyte glycolipids in Huntington's chorea. Neurology 19:489-493
279. Higatsberger MR, Sperk G, Bernheimer H, Shannak KS, Hornykiewicz O (1981) Striatal ganglioside levels in the rat following kainic acid lesions: comparison with Huntington's disease. Exp Brain Res 44:93-96
280. Desplats PA, Denny CA, Kass KE, Gilmartin T, Head SR, Sutcliffe JG, Seyfried TN, Thomas EA (2007) Glycolipid and ganglioside metabolism imbalances in Huntington's disease. Neurobiol Dis 27:265-277
281. Herrero MT, Kastner A, Perez-Otano I, Hirsch EC, Luquin MR, Javoy-Agid F, Del Rio J, Obeso JA, Agid Y (1993) Gangliosides and Parkinsonism. Neurology 43:2132-2134
282. Schneider JS, Roeltgen DP, Mancall EL, Chapas-Crilly J, Rothblat DS, Tatarian GT (1998) Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study. Neurology 50:1630-1636
283. Goettl VM, Wemlinger TA, Duchemin AM, Neff NH, Hadjiconstantinou M (1999) GM1 ganglioside restores dopaminergic neurochemical and morphological markers in aged rats. Neuroscience 92:991-1000
284. Tayebi N, Walker J, Stubblefield B, Orvisky E, LaMarca ME, Wong K, Rosenbaum H, Schiffmann R, Bembi B, Sidransky E (2003) Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 79:104-109
285. Zappia M, Crescibene L, Bosco D, Arabia G, Nicoletti G, Bagala A, Bastone L, Napoli ID, Caracciolo M, Bonavita S, Di Costanzo A, Gambardella A, Quattrone A (2002) Anti-GM1 ganglioside antibodies in Parkinson's disease. Acta Neurol Scand 106:54-57
286. Martinez Z, Zhu M, Han S, Fink AL (2007) GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry 46:1868-1877
287. Park JY, Kim KS, Lee SB, Ryu JS, Chung KC, Choo YK, Jou I, Kim J, Park SM (2009) On the mechanism of internalization of alpha-synuclein into microglia: roles of ganglioside GM1 and lipid raft. J Neurochem 110:400-411
288. Ryu JK, Shin WH, Kim J, Joe EH, Lee YB, Cho KG, Oh YJ, Kim SU, Jin BK (2002) Trisialoganglioside GT1b induces in vivo degeneration of nigral dopaminergic neurons: role of microglia. Glia 38:15-23
289. Prusiner SB (1997) Prion diseases and the BSE crisis. Science 278:245-251
290. Klein TR, Kirsch D, Kaufmann R, Riesner D (1998) Prion rods contain small amounts of two host sphingolipids as revealed by thin-layer chromatography and mass spectrometry. Biol Chem 379:655-666
291. Critchley P, Kazlauskaite J, Eason R, Pinheiro TJ (2004) Binding of prion proteins to lipid membranes. Biochem Biophys Res Commun 313:559-567
292. Sanghera N, Pinheiro TJ (2002) Binding of prion protein to lipid membranes and implications for prion conversion. J Mol Biol 315:1241-1256
293. Zhong J, Yang C, Zheng W, Huang L, Hong Y, Wang L, Sha Y (2009) Effects of lipid composition and phase on the membrane interaction of the prion peptide 106-126 amide. Biophys J 96:4610-4621
294. Fantini J, Garmy N, Mahfoud R, Yahi N (2002) Lipid rafts: structure, function and role in HIV, Alzheimer's and prion diseases. Expert Rev Mol Med 4:1-22
295. Kaneko K, Vey M, Scott M, Pilkuhn S, Cohen FE, Prusiner SB (1997) COOH-terminal sequence of the cellular prion protein directs subcellular trafficking and controls conversion into the scrapie isoform. Proc Natl Acad Sci USA 94:2333-2338
296. Stahl N, Baldwin MA, Hecker R, Pan KM, Burlingame AL, Prusiner SB (1992) Glycosylinositol phospholipid anchors of the scrapie and cellular prion proteins contain sialic acid. Biochemistry 31:5043-5053
297. Taraboulos A, Scott M, Semenov A, Avrahami D, Laszlo L, Prusiner SB (1995) Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J Cell Biol 129:121-132
298. Baron GS, Wehrly K, Dorward DW, Chesebro B, Caughey B (2002) Conversion of raft associated prion protein to the protease-resistant state requires insertion of PrP-res (PrP(Sc)) into contiguous membranes. Embo J 21:1031-1040
299. Keshet GI, Bar-Peled O, Yaffe D, Nudel U, Gabizon R (2000) The cellular prion protein colocalizes with the dystroglycan complex in the brain. J Neurochem 75:1889-1897
300. Loberto N, Prioni S, Bettiga A, Chigorno V, Prinetti A, Sonnino S (2005) The membrane environment of endogenous cellular prion protein in primary rat cerebellar neurons. J Neurochem 95:771-783
301. Rivaroli A, Prioni S, Loberto N, Bettiga A, Chigorno V, Prinetti A, Sonnino S (2007) Reorganization of prion protein membrane environment during low potassium-induced apoptosis in primary rat cerebellar neurons. J Neurochem 103:1954-1967
302. Ando S, Toyoda Y, Nagai Y, Ikuta F (1984) Alterations in brain gangliosides and other lipids of patients with Creutzfeldt-Jakob disease and subacute sclerosing panencephalitis (SSPE). Jpn J Exp Med 54:229-234
303. Ohtani Y, Tamai Y, Ohnuki Y, Miura S (1996) Ganglioside alterations in the central and peripheral nervous systems of patients with Creutzfeldt-Jakob disease. Neurodegeneration 5:331-338
304. Tamai Y, Ohtani Y, Miura S, Narita Y, Iwata T, Kaiya H, Namba M (1979) Creutzfeldt-Jakob disease\alteration in ganglioside sphingosine in the brain of a patient. Neurosci Lett 11:81-86
305. Yu RK, Ledeen RW, Gajdusek DC, Gibbs CJ (1974) Ganglioside changes in slow virus diseases: analyses of chimpanzee brains infected with kuru and Creutzfeldt-Jakob agents. Brain Res 70:103-112
306. Yu RK, Manuelidis EE (1978) Ganglioside alterations in guinea pig brains at end stages of experimental Creutzfeldt-Jakob disease. J Neurol Sci 35:15-23
307. Di Martino A, Safar J, Callegaro L, Salem N Jr, Gibbs CJ Jr (1993) Ganglioside composition changes in spongiform encephalopathies: analyses of 263K scrapie-infected hamster brains. Neurochem Res 18:907-913
308. Simpson MA, Cross H, Proukakis C, Priestman DA, Neville DC, Reinkensmeier G, Wang H, Wiznitzer M, Gurtz K, Verganelaki A, Pryde A, Patton MA, Dwek RA, Butters TD, Platt FM, Crosby AH (2004) Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase. Nat Genet 36:1225-1229
309. Yamashita T, Hashiramoto A, Haluzik M, Mizukami H, Beck S, Norton A, Kono M, Tsuji S, Daniotti JL, Werth N, Sandhoff R, Sandhoff K, Proia RL (2003) Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc Natl Acad Sci USA 100:3445-3449
310. Izumi T, Ogawa T, Koizumi H, Fukuyama Y (1993) Low levels of CSF gangliotetraose-series gangliosides in West syndrome: implication of brain maturation disturbance. Pediatr Neurol 9:293-296
311. Yu RK, Glaser GH (1975) Possible role of gangliosides in epilepsy: effects of epileptic seizures on cerebral gangliosides. Trans Am Neurol Assoc 100:261-263
312. Yu RK, Holley JA, Macala LJ, Spencer DD (1987) Ganglioside changes associated with temporal lobe epilepsy in the human hippocampus. Yale J Biol Med 60:107-117
313. Prinetti A, Rocchetta F, Costantino E, Frattini A, Caldana E, Rucci F, Bettiga A, Poliani PL, Chigorno V, Sonnino S (2009) Brain lipid composition in grey-lethal mutant mouse characterized by severe malignant osteopetrosis. Glycoconj J 26:623-633
314. Mocchetti I (2005) Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins. Cell Mol Life Sci 62:2283-2294
315. Schneider JS, Bradbury KA, Anada Y, Inokuchi J, Anderson DW (2006) The synthetic ceramide analog L-PDMP partially protects striatal dopamine levels but does not promote dopamine neuron survival in murine models of parkinsonism. Brain Res 1099:199-205
316. Inokuchi J (2009) Neurotrophic and neuroprotective actions of an enhancer of ganglioside biosynthesis. Int Rev Neurobiol 85:319-336
317. D'Azzo A (2003) Gene transfer strategies for correction of lysosomal storage disorders. Acta Haematol 110:71-85
318. Arfi A, Bourgoin C, Basso L, Emiliani C, Tancini B, Chigorno V, Li YT, Orlacchio A, Poenaru L, Sonnino S, Caillaud C (2005) Bicistronic lentiviral vector corrects beta-hexosaminidase deficiency in transduced and cross-corrected human Sandhoff fibroblasts. Neurobiol Dis 20:583-593
319. Villani GR, Follenzi A, Vanacore B, Di Domenico C, Naldini L, Di Natale P (2002) Correction of mucopolysaccharidosis type IIIb fibroblasts by lentiviral vector-mediated gene transfer. Biochem J 364:747-753
320. Desnick RJ, Schuchman EH (2002) Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet 3:954-966
321. Bengtsson BA, Johansson JO, Hollak C, Linthorst G, FeldtRasmussen U (2003) Enzyme replacement in Anderson-Fabry disease. Lancet 361:352
322. Grabowski GA, Hopkin RJ (2003) Enzyme therapy for lysosomal storage disease: principles, practice, and prospects. Annu Rev Genomics Hum Genet 4:403-436
323. Dhami R, Schuchman EH (2004) Mannose 6-phosphate receptor-mediated uptake is defective in acid sphingomyelinase-deficient macrophages: implications for Niemann-Pick disease enzyme replacement therapy. J Biol Chem 279:1526-1532
324. Sawkar AR, Cheng WC, Beutler E, Wong CH, Balch WE, Kelly JW (2002) Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci USA 99:15428-15433
325. Lachmann RH (2003) Miglustat. Oxford glycosciences/actelion. Curr Opin Investig Drugs 4:472-479
326. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, Platt F, Butters T, Dwek R, Moyses C, Gow I, Elstein D, Zimran A (2000) Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355:1481-1485
327. Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, Mistry P (2005) Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol 80:223-229
328. Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE (2007) Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 6:765-772
329. Platt FM, Neises GR, Reinkensmeier G, Townsend MJ, Perry VH, Proia RL, Winchester B, Dwek RA, Butters TD (1997) Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 276:428-431
330. Fortin DL, Troyer MD, Nakamura K, Kubo S, Anthony MD, Edwards RH (2004) Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci 24(30):6715-6723